FMTX News and Press, Forma Therapeutics Holdings Inc. From 03/30/21

Forma Therapeutics Holdings, Inc. (FMTX) Q4 2020 Earnings Conference Call March 30, 2021 08:00 AM ET Company Participants Mario Corso - Senior Director-Investor Relations Frank Lee - President & Chief Executive Officer Patrick Kelly - Chief Medical Officer Dave Cook - Chief Scientific Off...

Forma Therapeutics (FMTX) announces new data from its ongoing Phase 1 trial of FT-4202 in patients with sickle cell disease ((SCD)).The new findings include data analysis from the second cohort of patients receiving 600 mg of FT-4202 or placebo once daily for 14 days and a 7-day follow up per...

Forma Therapeutics (FMTX): Q4 GAAP EPS of -$0.68 beats by $0.12.Cash, cash equivalents and marketable securities of $645.6MPress Release For further details see: Forma Therapeutics EPS beats by $0.12

Strong organizational foundation laid in 2020; continued pipeline execution amid COVID-19 and raised gross capital of $595.1 million Key 2020 pipeline achievements include proof of concept for FT-4202 in sickle cell disease; successful interim analysis of registrational Phase ...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release fourth quarter and year-end 2020 financial results Tuesday, March 30, 2021. Forma management will host ...

Stephen Mandel’s 13F portfolio value increased ~19% from $23.20B to $27.51B. The number of positions increased from 32 to 41. Lone Pine Capital increased MercadoLibre and DexCom while dropping PayPal and Capital One Financial. The top three positions are Shopify, Coupa Soft...

The first patient has been dosed in Forma Therapeutics' (FMTX) Phase 1 clinical trial evaluating FT-7051, a selective inhibitor of CBP/p300, a known co-activator of the androgen receptor in men with metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 will evaluate safety and ...

Phase 1 study includes late-line patients and patients with AR-v7 splice variants for whom there are no approved therapies FT-7051 is a selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300) and a co-activator of androgen receptor In prostate c...

Strong pipeline progress in 2020 positions company well for 2021 Established proof of concept in SCD for FT-4202 Potential transformative treatment profile for IDH1 inhibitor olutasidenib in R/R/ AML Enrolling Phase 1 FT-7051 trial for prostate cancer - includi...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that Selwyn M. Vickers, M.D., F.A.C.S., has been elected to serve on the company’s board of directors. This press...